Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 09, 2016 1:21 PM ET

Healthcare Equipment and Supplies

Company Overview of Veracyte, Inc.

Company Overview

Veracyte, Inc. operates as a molecular diagnostics company in the United States. It operates in the field of molecular cytology with genomic solutions that resolve diagnostic ambiguity and enable physicians to make informed treatment decisions at an early stage in patient care. The company offers Afirma Thyroid FNA Analysis solution for use in thyroid cancer diagnosis; cytopathology testing services; and the Afirma Malignancy Classifiers, which comprise the genomic tests for medullary thyroid cancer and BRAF V600E mutation status. It also develops a product to preoperatively identify idiopathic pulmonary fibrosis among patients presenting with a suspected interstitial lung disease; and the P...

7000 Shoreline Court

Suite 250

South San Francisco, CA 94080

United States

Founded in 2006

167 Employees

Phone:

650-243-6300

Fax:

650-243-6301

Key Executives for Veracyte, Inc.

Co-Founder, Chief Executive Officer, President, Director and Member of Non-Management Equity Award Committee
Age: 57
Total Annual Compensation: $425.0K
Chief Financial Officer, Principal Accounting Officer and Member of Non-Management Equity Award Committee
Age: 55
Total Annual Compensation: $300.0K
Chief Operating Officer
Age: 46
Total Annual Compensation: $341.2K
Compensation as of Fiscal Year 2014.

Veracyte, Inc. Key Developments

Veracyte Announces Publication of Long-Term Clinical Utility Study for the Afirma® Gene Expression Classifier

Veracyte, Inc. announced that data demonstrating the ability of the Afirma Gene Expression Classifier (GEC) to reduce thyroid surgeries during three years of follow-up were published online in Endocrine Practice, the journal of the American Association of Clinical Endocrinologists (AACE). The study provides the longest-term follow-up information published to date for the genomic test, which is used to identify patients whose thyroid nodules are benign following inconclusive fine needle aspiration (FNA) biopsy results, so that they can potentially avoid unnecessary diagnostic surgery and be monitored with ultrasound imaging instead. Researchers assessed surgery rates for patients with benign Afirma GEC results who were tested at 16 community-based practices across the United States and were followed for 36 months. They found that 82.7% of patients (81 out of 98) with a benign Afirma GEC result avoided surgery during the follow-up period, with the majority (88%) of any surgeries occurring within the first two years. In comparison, the historical rate of surgery avoidance is just 26% among thyroid nodule patients with indeterminate cytopathology results.

Veracyte, Inc. Announces Expansion to New South San Francisco Facility

Veracyte, Inc. announced that the company is relocating to expanded laboratory and corporate space within South San Francisco. The new space more than doubles the space Veracyte currently occupies, in order to accommodate the company's strong growth as it offers genomic tests designed to improve disease diagnosis, thus helping patients avoid unnecessary surgeries and taking costs out of the healthcare system.

Veracyte, Inc. Presents at JPMorgan 34th Annual Healthcare Conference, Jan-14-2016 11:00 AM

Veracyte, Inc. Presents at JPMorgan 34th Annual Healthcare Conference, Jan-14-2016 11:00 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, California, United States. Speakers: Bonnie H. Anderson, Co-Founder, Chief Executive Officer, President, Director and Member of Non-Management Equity Award Committee.

Similar Private Companies By Industry

Company Name Region
AxialMED, Inc. United States
U.S. Biopsy LLC United States
Cuff-Mate, Inc. United States
Hind-Sight Industries, Inc. United States
Paragon Vision Sciences, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
April 22, 2015
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Veracyte, Inc., please visit www.veracyte.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.